Impact of intestinal microbiome on infections, course and outcome of haematological-oncological patients treated with chemotherapy

Impact of intestinal microbiome on infections, course and outcome of haematological-oncological patients treated with chemotherapy - MicroIntest

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011674

Enrollment

Registered

2017-02-03

Start date

2017-09-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gut microbiome C92.0

Interventions

Group 1: Investigation of stool samples regarding gut microbiome and multi-resistant bacteria of AML patients before, during and after intensive chemotherapy cycles (impact of chemotherapeutic agents

longitudinal inverstigation of several cycles

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age =18 years; 2. Written informed consent; 3. AML first diagnose; 4. Therapy with repetitive chemotherapy cycles, inclusive allogeneic or autologous stem cell transplantation

Exclusion criteria

Exclusion criteria: 1. Antibiotic therapy =4 weeks before study inclusion; 2. AML teatment with cytoreductive long-term therapy (e. g. hydroxyurea); 3. Stool transplantation (e. g. due to relapsed C. difficile infection)

Design outcomes

Primary

Measure	Time frame
1. Changes of intestinal microbiome after chemtherapy	—

Secondary

Measure	Time frame
1. Impact on course and outcome of disease; 2. Association between mixture of microbiome and MRGN colonisation or infection	—

Countries

Germany

Contacts

Public ContactChristine Friedrichs

Universitätsklinikum Magdeburg A.ö.R.Klinik für Hämatologie und OnkologieStudiensekretariat

christine.friedrichs@med.ovgu.de+49 (0) 391 67 13147

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026